ArticleScientific reports2025
Independent validation of lung adenocarcinoma prognostic risk scores incorporating cholesterol and estrogen metabolism related transcriptional biomarkers.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We investigated the prognostic significance of cholesterol metabolism-related genes (CMRGs) and estrogen metabolism-related genes (EMRGs) in lung adenocarcinoma (LUAD). Transcriptomic and clinical data from the cancer genome atlas (TCGA) and gene expression omnibus (GEO) databases were analyzed. Iterative sure independence screening and least absolute shrinkage and selection operator (ISIS-LASSO) Cox regression identified prognostic CMRGs and EMRGs. Two risk scores-Cholescore and Estrogenscore-were constructed and validated. High Cholescore was associated with poor overall survival (OS), reduced immune infiltration, low immune checkpoint expression, and high tumor purity, suggesting an immunosuppressive tumor microenvironment. Estrogenscore also independently predicted LUAD prognosis. Mediation analysis revealed that estrogen-related pathways partially mediated the impact of cholesterol metabolism on prognosis. A significant interaction between Cholescore and Estrogenscore was identified, and patients with both high scores had the worst OS and lowest predicted immunotherapy benefit. Combining the two scores significantly improved the area under the curve (AUC) for 1-5 years OS prediction. These findings suggest that integrating cholesterol and estrogen metabolism signatures can improve LUAD prognostic stratification and provide molecular insights into tumor-immune interactions and immunotherapy response prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.